[1]Patent:WO2008/1101,2008,A2.Locationinpatent:Page/Pagecolumn329-330
[2]Patent:WO2008/7113,2008,A2.Locationinpatent:Page/Pagecolumn156
[3]JournalofMedicinalChemistry,2008,vol.51,p.4986-4999
[4]Patent:WO2005/12256,2005,A1.Locationinpatent:Page/Pagecolumn210
[5]Patent:WO2008/9954,2008,A1.Locationinpatent:Page/Pagecolumn80-81
[6]Patent:CN109705090,2019,A.Locationinpatent:Paragraph0106;0116-0118
75-75-2
[1]Patent:WO2006/77426,2006,A2.Locationinpatent:Page/Pagecolumn93
64-19-7
[1]Patent:WO2006/77426,2006,A2.Locationinpatent:Page/Pagecolumn95
[2]Patent:WO2006/77425,2006,A1.Locationinpatent:Page/Pagecolumn209;226
[3]Patent:WO2006/77424,2006,A1.Locationinpatent:Page/Pagecolumn189;212
[4]Patent:WO2008/1101,2008,A2.Locationinpatent:Page/Pagecolumn331-332
[5]Patent:WO2008/7113,2008,A2.Locationinpatent:Page/Pagecolumn157-158
[6]Patent:WO2008/9954,2008,A1.Locationinpatent:Page/Pagecolumn82-83;95
[1]Patent:WO2006/77426,2006,A2.Locationinpatent:Page/Pagecolumn93
[2]Patent:WO2006/77426,2006,A2.Locationinpatent:Page/Pagecolumn94-95
[3]Patent:WO2006/77425,2006,A1.Locationinpatent:Page/Pagecolumn209;226
[4]Patent:WO2006/77424,2006,A1.Locationinpatent:Page/Pagecolumn189;212
[5]Patent:WO2008/1101,2008,A2.Locationinpatent:Page/Pagecolumn331
[6]Patent:WO2008/7113,2008,A2.Locationinpatent:Page/Pagecolumn157-158
[7]Patent:WO2008/9954,2008,A1.Locationinpatent:Page/Pagecolumn82;94-95
844442-38-2
64-19-7
[1]Patent:WO2006/77426,2006,A2.Locationinpatent:Page/Pagecolumn30
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update.
Journal: TheScientificWorldJournal 20120101
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111030
Title: A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20110901
Title: Prediction of cyclin-dependent kinase 2 inhibitor potency using the fragment molecular orbital method.
Journal: Journal of cheminformatics 20110101
Title: Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammation.
Journal: PloS one 20110101
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology 20101124
Title: AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.
Journal: Oncogene 20100422
Title: AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples.
Journal: Molecular cancer therapeutics 20100401
Title: Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Journal: Molecular cancer therapeutics 20090201
Title: Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.
Journal: Journal of medicinal chemistry 20080828
Title: Santo L, et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene. 2010 Apr 22;29(16):2325-36.
Title: Squires MS, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines.
Title: Squires MS, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther. 2010 Apr;9(4):920-8.
